請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17008完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張明富(Ming-Fu Chang) | |
| dc.contributor.author | Linda Tzu-Ling Tseng | en |
| dc.contributor.author | 曾子玲 | zh_TW |
| dc.date.accessioned | 2021-06-07T23:52:57Z | - |
| dc.date.copyright | 2014-02-25 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-11-12 | |
| dc.identifier.citation | Abel, E. D. (2004a). Glucose transport in the heart. Front. Biosci. 9, 201-15.
Abel, E. D. (2004b). Insulin signaling in heart muscle: lessons from genetically engineered mouse models. Curr. Hypertens. Rep. 6, 416-23. Abel, E. D., Kaulbach, H. C., Tian, R., Hopkins, J. C., Duffy, J., Doetschman, T., Minnemann, T., Boers, M. E., Hadro, E., Oberste-Berghaus, C. et al. (1999). Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 104, 1703-14. Backer, J. M., Shoelson, S. E., Haring, E. and White, M. F. (1991). Insulin receptors internalize by a rapid, saturable pathway requiring receptor autophosphorylation and an intact juxtamembrane region. J. Cell Biol. 115, 1535-45. Bairstow, S. F., Ling, K., Su, X., Firestone, A. J., Carbonara, C. and Anderson, R. A. (2006). Type Igamma661 phosphatidylinositol phosphate kinase directly interacts with AP2 and regulates endocytosis. J. Biol. Chem. 281, 20632-42. Balbis, A., Baquiran, G., Mounier, C. and Posner, B. I. (2004). Effect of insulin on caveolin-enriched membrane domains in rat liver. J Biol Chem 279, 39348-57. Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J. and Kelly, D. P. (2000). Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723-30. Baron, A. D. (1993). Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone. Baillieres. Clin. Endocrinol. Metab. 7, 961-87. Barth, A. S., Kuner, R., Buness, A., Ruschhaupt, M., Merk, S., Zwermann, L., Kaab, S., Kreuzer, E., Steinbeck, G., Mansmann, U. et al. (2006). Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J. Am. Coll. Cardiol. 48, 1610-7. 82 Belke, D. D., Betuing, S., Tuttle, M. J., Graveleau, C., Young, M. E., Pham, M., Zhang, D., Cooksey, R. C., McClain, D. A., Litwin, S. E. et al. (2002). Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109, 629-39. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H. and Yancopoulos, G. D. (1991). ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-75. Braz, J. C., Bueno, O. F., Liang, Q., Wilkins, B. J., Dai, Y. S., Parsons, S., Braunwart, J., Glascock, B. J., Klevitsky, R., Kimball, T. F. et al. (2003). Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 111, 1475-86. Ceresa, B. P., Kao, A. W., Santeler, S. R. and Pessin, J. E. (1998). Inhibition of clathrin-mediated endocytosis selectively attenuates specific insulin receptor signal transduction pathways. Mol. Cell Biol. 18, 3862-70. Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R. M., Schneider, M. D., Brako, F. A., Xiao, Y. et al. (2004). Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245-50. Claycomb, W. C., Lanson, N. A., Jr., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A. and Izzo, N. J., Jr. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U S A 95, 2979-84. Cocucci, E., Aguet, F., Boulant, S. and Kirchhausen, T. (2012). The first five seconds in the life of a clathrin-coated pit. Cell 150, 495-507. 83 Condorelli, G., Drusco, A., Stassi, G., Bellacosa, A., Roncarati, R., Iaccarino, G., Russo, M. A., Gu, Y., Dalton, N., Chung, C. et al. (2002). Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U S A 99, 12333-8. Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J. et al. (2002). Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737-49. Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S., Korner, R., Greff, Z., Keri, G., Stemmann, O. and Mann, M. (2008). Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48. DeBosch, B. J. and Muslin, A. J. (2008). Insulin signaling pathways and cardiac growth. J. Mol. Cell Cardiol. 44, 855-64. Del Re, D. P., Matsuda, T., Zhai, P., Gao, S., Clark, G. J., Van Der Weyden, L. and Sadoshima, J. (2010). Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J. Clin. Invest. 120, 3555-67. Eden, E. R., White, I. J., Tsapara, A. and Futter, C. E. (2010). Membrane contacts between endosomes and ER provide sites for PTP1B-epidermal growth factor receptor interaction. Nat. Cell Biol. 12, 267-72. Fagerholm, S., Ortegren, U., Karlsson, M., Ruishalme, I. and Stralfors, P. (2009). Rapid insulin-dependent endocytosis of the insulin receptor by caveolae in primary adipocytes. PLoS One 4, e5985. Fang, K. M., Lee, A. S., Su, M. J., Lin, C. L., Chien, C. L. and Wu, M. L. (2008). Free fatty acids act as endogenous ionophores, resulting in Na+ and Ca2+ influx and myocyte apoptosis. Cardiovasc. Res. 78, 533-45. 84 Frangioni, J. V., Beahm, P. H., Shifrin, V., Jost, C. A. and Neel, B. G. (1992). The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 68, 545-60. Friehs, I., Moran, A. M., Stamm, C., Colan, S. D., Takeuchi, K., Cao-Danh, H., Rader, C. M., McGowan, F. X. and del Nido, P. J. (1999). Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 100, II187-93. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G. and Bastiaens, P. I. (2002). Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708-11. Heineke, J. and Molkentin, J. D. (2006). Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600. Henne, W. M., Boucrot, E., Meinecke, M., Evergren, E., Vallis, Y., Mittal, R. and McMahon, H. T. (2010). FCHo proteins are nucleators of clathrin-mediated endocytosis. Science 328, 1281-4. Hsu, W. C., Tzen, K. Y., Huy, P. T., Duet, M. and Yeh, T. H. (2009). An animal model of central auditory pathway imaging in the rat brain by high resolution small animal positron emission tomography. Acta. Otolaryngol. 129, 423-8. Huang, C., Jiang, J. Y., Chang, S. C., Tsay, Y. G., Chen, M. R. and Chang, M. F. (2013). Nuclear export signal-interacting protein forms complexes with lamin A/C-Nups to mediate the CRM1-independent nuclear export of large hepatitis delta antigen. J Virol 87, 1596-604. Jackson, L. P., Kelly, B. T., McCoy, A. J., Gaffry, T., James, L. C., Collins, B. M., Honing, S., Evans, P. R. and Owen, D. J. (2010). A large-scale conformational change couples membrane recruitment to cargo binding in the AP2 clathrin adaptor complex. Cell 141, 1220-9. 85 Jose, M., Biosca, J. A., Trujillo, R. and Itarte, E. (1993). Characterization of the hepatic insulin receptor undergoing internalization through clathrin-coated vesicles and endosomes. FEBS Lett. 334, 286-8. Kelly, B. T., McCoy, A. J., Spate, K., Miller, S. E., Evans, P. R., Honing, S. and Owen, D. J. (2008). A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. Nature 456, 976-979. Kukulski, W., Schorb, M., Kaksonen, M. and Briggs, J. A. (2012). Plasma Membrane Reshaping during Endocytosis Is Revealed by Time-Resolved Electron Tomography. Cell 150, 508-20. Laustsen, P. G., Russell, S. J., Cui, L., Entingh-Pearsall, A., Holzenberger, M., Liao, R. and Kahn, C. R. (2007). Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell Biol. 27, 1649-64. Lehman, J. J. and Kelly, D. P. (2002). Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail. Rev. 7, 175-85. Lemmon, M. A. and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-34. Leto, D. and Saltiel, A. R. (2012). Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383-96. Liang, Q., Bueno, O. F., Wilkins, B. J., Kuan, C. Y., Xia, Y. and Molkentin, J. D. (2003). c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22, 5079-89. Liao, A. H., Cheng, Y. C., Weng, C. H., Tsai, T. F., Lin, W. H., Yeh, S. H., Yeh, W. C. and Li, P. C. (2008). Characterization of malignant focal liver lesions with contrast-enhanced 40 MHz ultrasound imaging in hepatitis B virus X transgenic mice: a feasibility study. Ultrason. Imaging 30, 203-16. 86 Lin, J. W., Ju, W., Foster, K., Lee, S. H., Ahmadian, G., Wyszynski, M., Wang, Y. T. and Sheng, M. (2000). Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat. Neurosci. 3, 1282-90. Ling, H., Zhang, T., Pereira, L., Means, C. K., Cheng, H., Gu, Y., Dalton, N. D., Peterson, K. L., Chen, J., Bers, D. et al. (2009). Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230-40. McCarthy, C. F., Fraser, I. D. and Read, A. E. (1966). Plasma lactate dehydrogenase in megaloblastic anaemia. J. Clin. Pathol. 19, 51-4. McMullen, J. R., Sherwood, M. C., Tarnavski, O., Zhang, L., Dorfman, A. L., Shioi, T. and Izumo, S. (2004). Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109, 3050-5. Molkentin, J. D. (2004). Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 63, 467-75. Montessuit, C. and Thorburn, A. (1999). Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists. J. Biol. Chem. 274, 9006-12. Motley, A., Bright, N. A., Seaman, M. N. and Robinson, M. S. (2003). Clathrin-mediated endocytosis in AP-2-depleted cells. J. Cell. Biol. 162, 909-18. Mudd, J. O. and Kass, D. A. (2008). Tackling heart failure in the twenty-first century. Nature 451, 919-28. Muniyappa, R., Montagnani, M., Koh, K. K. and Quon, M. J. (2007). Cardiovascular actions of insulin. Endocr. Rev. 28, 463-91. Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S. and Bunnett, N. W. (2009). Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. U. S. A. 106, 17615-22. 87 Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T. and Bonifacino, J. S. (1995). Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 269, 1872-5. Olsen, J. V., Vermeulen, M., Santamaria, A., Kumar, C., Miller, M. L., Jensen, L. J., Gnad, F., Cox, J., Jensen, T. S., Nigg, E. A. et al. (2010). Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal 3, ra3. Owen, D. J. and Evans, P. R. (1998). A structural explanation for the recognition of tyrosine-based endocytotic signals. Science 282, 1327-32. Ritter, B., Denisov, A. Y., Philie, J., Deprez, C., Tung, E. C., Gehring, K. and McPherson, P. S. (2004). Two WXXF-based motifs in NECAPs define the specificity of accessory protein binding to AP-1 and AP-2. EMBO J. 23, 3701-10. Rutsch, F., Gailus, S., Miousse, I. R., Suormala, T., Sagne, C., Toliat, M. R., Nurnberg, G., Wittkampf, T., Buers, I., Sharifi, A. et al. (2009). Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B12 metabolism. Nat. Genet. 41, 234-9. Saltiel, A. R. and Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806. Schafers, K. P., Stegger, L., Barnard, C., Kriens, M., Hermann, S., Schober, O. and Schafers, M. (2005). ECG-triggered high-resolution positron emission tomography: a breakthrough in cardiac molecular imaging of mice. Eur. J. Nucl. Med. Mol. Imaging 32, 383. Shimizu, I., Minamino, T., Toko, H., Okada, S., Ikeda, H., Yasuda, N., Tateno, K., Moriya, J., Yokoyama, M., Nojima, A. et al. (2010). Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120, 1506-14. 88 Shioi, T., McMullen, J. R., Tarnavski, O., Converso, K., Sherwood, M. C., Manning, W. J. and Izumo, S. (2003). Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664-70. Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., Colucci, W. S. and Walsh, K. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108-18. Su, M. J., Chang, G. J., Wu, M. H. and Kuo, S. C. (1997). Electrophysiological basis for the antiarrhythmic action and positive inotropy of HA-7, a furoquinoline alkaloid derivative, in rat heart. Br. J. Pharmacol. 122, 1285-98. Sylvius, N., Tesson, F., Gayet, C., Charron, P., Benaiche, A., Peuchmaurd, M., Duboscq-Bidot, L., Feingold, J., Beckmann, J. S., Bouchier, C. et al. (2001). A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16. Am. J. Hum. Genet. 68, 241-6. Taegtmeyer, H., Wilson, C. R., Razeghi, P. and Sharma, S. (2005). Metabolic energetics and genetics in the heart. Ann. N. Y. Acad. Sci. 1047, 208-18. Tosoni, D., Puri, C., Confalonieri, S., Salcini, A. E., De Camilli, P., Tacchetti, C. and Di Fiore, P. P. (2005). TTP specifically regulates the internalization of the transferrin receptor. Cell 123, 875-88. Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H. and Stoffel, M. (2011). MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649-53. Traub, L. M. (2009). Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat. Rev. Mol. Cell Biol. 10, 583-96. Walker, P. S., Ramlal, T., Sarabia, V., Koivisto, U. M., Bilan, P. J., Pessin, J. E. and Klip, A. (1990). Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. J. Biol. Chem. 265, 1516-23. 89 Wang, Y. H., Chang, S. C., Huang, C., Li, Y. P., Lee, C. H. and Chang, M. F. (2005). Novel nuclear export signal-interacting protein, NESI, critical for the assembly of hepatitis delta virus. J. Virol. 79, 8113-20. Ward, C. W., Lawrence, M. C., Streltsov, V. A., Adams, T. E. and McKern, N. M. (2007). The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. Trends Biochem. Sci. 32, 129-37. Warren, R. A., Green, F. A. and Enns, C. A. (1997). Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor. J. Biol. Chem. 272, 2116-21. Woods, A. J., Roberts, M. S., Choudhary, J., Barry, S. T., Mazaki, Y., Sabe, H., Morley, S. J., Critchley, D. R. and Norman, J. C. (2002). Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J. Biol. Chem. 277, 6428-37. Wu, X., Zhang, T., Bossuyt, J., Li, X., McKinsey, T. A., Dedman, J. R., Olson, E. N., Chen, J., Brown, J. H. and Bers, D. M. (2006). Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J. Clin. Invest. 116, 675-82. Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A. and Olson, E. N. (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-88. Zisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B. B., Wojtaszewski, J. F., Hirshman, M. F., Virkamaki, A., Goodyear, L. J. et al. (2000). Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6, 924-8. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17008 | - |
| dc.description.abstract | 細胞內的能量恆定調節是維繫細胞正常生理的重要因素，而這能量的恆定調
節的失衡則是導致許多疾病發生的開端。lmbrd1 基因所表達出的LMBD1 蛋白質 是一包含九個預測穿膜結構的膜蛋白質。最近的研究顯示細胞內溶酶體中維他命 B12 的細胞質輸出作用與 lmbrd1 基因的對位雙變異有密切關係，會造成病人的 維生素B12 利用缺乏症，導致新生兒許多早期病理症狀。在本研究中，發現只 要有一 lmbrd1 基因對位的變異，便會導致非維生素B12 利用缺乏相關的心臟疾 病。利用 lmbrd1 基因對位單一變異(lmbrd +/-)的小鼠模式系統，發現 18FDG 在 心臟組織有大量累積，並對外加胰島素的再誘發作用，無明顯反映在額外的 18FDG 的增加累積。並發現在此 lmbrd1+/- 小鼠心臟的胰島素接受體是處於持續 活化的狀態，且心博與心肌收縮也異常增加。導致代償性的心肌肥大與局部受損 相關的纖維化病變。隨著lmbrd1+/-小鼠的老化，其心臟的左心室血液射出分率降 低，伴隨著心室功能的惡化。進一步利用初繼代培養大鼠心室細胞，進行 lmbrd1 基因的抑低表現調控，發現其胰島素受體的自身活化提升，並造成下游Akt 激 酶的活化也提升。以共軛焦螢光顯微鏡與活細胞全反射螢光顯微鏡的觀察結果， 發現 LMBD1 蛋白會與胰島素受體與clathrin 聚集在細胞膜同一位置，並會因胰 島素誘發胰島素受體的內吞作用時，同步一起進入細胞內。利用定點突變置換 LMBD1 蛋白質上可能的AP-2 結合位的胺基酸，結果發現 LMBD1 包含兩個與 胰島素受體細胞內吞作用調節有關的區段。綜合本研究的結果，此 lmbrd1 基因 所表達出的 LMBD1 蛋白會參與調節心臟中胰島素受體的細胞內吞作用，並與 其下游相關活性訊息傳遞調控相關，且從 lmbrd1+/- 小鼠模式系統發現，其對位 單一變異會導致心臟左心室心肌肥大及相關病變可能是與其調控胰島素受體細 胞內吞作用與其活性有密切關係。 | zh_TW |
| dc.description.abstract | Energy homeostasis is crucial in maintaining normal biological functions of
cells. Disturbances in such balance often lead to various diseases. Limb region 1 (LMBR1) domain containing 1 gene (lmbrd1) encodes a nine-transmembrane LMBD1 protein. Previous study demonstrated that double allele frameshift mutation of lmbrd1 is associated with lysosomal cobalamin export deficiency, suggesting the participation of LMBD1 in the export of cobalamin from lysosome to the cyotsol. In this study, we have distinguished that heterozygous deletion of lmbrd1 is sufficient for causing cardiac diseases through a pathway independent of the vitamin B12 metabolic defect. lmbrd1 ubiquitous heterozygous knockout lmbrd1+/- mice exhibited increase in myocardial glucose uptake and insulin receptor signaling that were insensitive to the administration of additional insulin. Consistent with the constitutively activated insulin receptor signaling, lmbrd1+/- mice exhibited an increase in heart rate and cardiac muscle contractility, leading to the development of compensated pathological hypertrophy and fibrosis. As lmbrd1+/- mice aged, the decrease in ejection fraction and fraction shortening showed signs of ventricular function deterioration. Additional studies using primary ventricular cells demonstrated that knockdown of lmbrd1 resulted in an elevated signaling of insulin receptor (IR) and its downstream molecule Akt. Confocal and live total internal 3 reflection fluorescence microscopy showed that LMBD1 colocalized and co-internalized with clathrin and IR upon insulin induction. Mutagenesis and phenotypic rescue studies further identified the motifs responsible for assisting the endocytosis of IR. Altogether, LMBD1 plays a regulatory role in the plasma membrane as an adaptor protein for insulin receptor endocytosis and modulates the IR metabolic signaling pathway. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T23:52:57Z (GMT). No. of bitstreams: 1 ntu-102-F95442025-1.pdf: 5030663 bytes, checksum: e013dea6beea33a8231723e5f867dbf3 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 中文摘要 ......................................................................................................................... 1
Abstract ............................................................................................................................ 2 Abbreviation .................................................................................................................... 4 Introduction ..................................................................................................................... 7 Specific Aim .................................................................................................................. 14 Material and Methods .................................................................................................... 15 1.1 Pharmaceuticals ........................................................................................................... 15 1.2 Mouse Model .............................................................................................................. 17 1.3 Cell Lines and Transfection ........................................................................................ 17 1.4 Medium and Reagents ................................................................................................. 18 1.5 Enzymes ...................................................................................................................... 19 1.6 Kits .............................................................................................................................. 19 1.7 Plasmids ...................................................................................................................... 20 1.8 Antibodies ................................................................................................................... 21 1.9 Analytical Equipments and Software .......................................................................... 23 Methods ................................................................................................................ 23 2.1 Restriction Enzyme Digestion ..................................................................................... 23 2.2 Ligation Reaction ........................................................................................................ 23 2.3 Bacterial Transformation ............................................................................................. 24 2.4 Mini/Midi Preparation of Plasmid DNA ..................................................................... 24 2.5 Plasmids Constructions ............................................................................................... 24 2.6 DNA Agarose Gel Electrophoresis ............................................................................. 28 2.7 Primary Ventricular Cardiomyocyte Isolation and NucleofectorTM Transfection ....... 28 2.8 HL-1 and H9C2 Cardiomyocyte Culture and Transfection ........................................ 29 2.9 Protein Extraction from Cultured Cells ....................................................................... 30 ii 2.10 Protein Extraction from Mouse Tissues .................................................................... 30 2.11 Protein Quantification ............................................................................................... 31 2.12 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) .......... 31 2.13 Coomassie Blue Staining .......................................................................................... 32 2.14 Western Blot Analysis ............................................................................................... 33 2.15 Immunoprecipitation Assay ...................................................................................... 33 2.16 Continuous Opti-Prep gradient .................................................................................. 34 2.17 Immunofluorescence Assay ...................................................................................... 35 2.18 Total Internal Reflection Fluorescence Microscopy (TIRF) ..................................... 35 2.19 Surface Biotinylation Assay ...................................................................................... 37 2.20 Flow Cytometry Assay .............................................................................................. 37 2.21 Mouse genotyping ..................................................................................................... 38 2.22 Mouse Blood Sampling ............................................................................................. 38 2.23 Glucose Tolerance Test (GTT) ................................................................................. 39 2.24 Insulin Tolerance Test (ITT) ..................................................................................... 39 2.25 Micro-PET/CT .......................................................................................................... 39 2.26 Cardiac Ultrasound .................................................................................................... 40 2.27 Immunohistochemitry ............................................................................................... 41 Results ........................................................................................................................... 42 Discussion ...................................................................................................................... 54 Tables and Figures ......................................................................................................... 59 Table 1 Mouse heart to body weight ratio in wildtype and lmbrd1+/- mice ...................... 59 Table 2 Mouse blood parameters ...................................................................................... 60 Figure 1 Electrocardiography of the wildtype and lmbrd1+/- mice exhibit distinct pattern. .......................................................................................................................................... 61 Figure 2 18F-D-glucose (FDG) uptake profile in mice. ..................................................... 62 Figure 3 Myocardial glucose uptake in lmbrd1+/- and wildtype mouse hearts. ................. 63 iii Figure 4 Glucose and insulin tolerance in wildtype and lmbrd1+/- mice. .......................... 64 Figure 5 LMBD1 regulates cardiac glucose uptake through the IR-PI3K-Akt pathway .. 65 Figure 6 Accumulation of IR in the PM of lmbrd1+/- mouse cardiomyocytes. .................. 66 Figure 7 PM-localized LMBD1 participates in the endocytosis of IR but not TrfR. ........ 67 Figure 8 Knockdown of lmbrd1 results in the retention of IR. ......................................... 68 Figure 9 The participation of LMBD1 in CCV. ................................................................ 69 Figure 10 Putative functional motifs and subcellular localization of LMBD1. ................ 70 Figure 11 LMBD1 co-complexes with AP2 and CHC. ..................................................... 71 Figure 12 LMBD1 specifically interacts with IR. ............................................................. 72 Figure 13 Live TIRF microscopic images of a single molecule movement upon insulin induction. ........................................................................................................................... 73 Figure 14 YXXΦ and WXXF motifs are critical for the binding of LMBD1 to AP-2. .... 74 Figure 15 lmbrd1+/- mice exhibit cardiac hypertrophy ...................................................... 75 Figure 16 Development of cardiomyopathy in lmbrd1+/- mice. ......................................... 76 Figure 17 lmbrd1+/- mice exhibits cardiac function abnormalty. ...................................... 77 Figure 18 lmbrd1 knockdown cells exhibit an increase in vitmentin expression. ............. 78 Figure 19 Colocalization of LMBRD1 and PTP1B. ......................................................... 79 Figure 20 Effects of LMBD1 knock down on hearts and kidneys of Wt and lmbrd1+/- mice. .......................................................................................................................................... 80 References ..................................................................................................................... 81 Publication ..................................................................................................................... 90 | |
| dc.language.iso | en | |
| dc.subject | 胰島素 | zh_TW |
| dc.subject | 心肌 | zh_TW |
| dc.subject | 細胞訊息 | zh_TW |
| dc.subject | Insulin Receptor | en |
| dc.subject | fibrosis | en |
| dc.subject | Cardiac hypertrophy | en |
| dc.subject | Clathrin | en |
| dc.subject | AP-2 | en |
| dc.subject | LMBD1 | en |
| dc.subject | LMBRD1 | en |
| dc.title | LMBD1 蛋白質於心肌之胰島素訊息調節 | zh_TW |
| dc.title | The role of LMBD1 protein in regulating
cardiac insulin signaling | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 林榮耀(Jung-Yaw Lin),嚴仲陽,楊偉勛,陳瑞華,林敬哲 | |
| dc.subject.keyword | 心肌,胰島素,細胞訊息, | zh_TW |
| dc.subject.keyword | LMBD1,LMBRD1,Insulin Receptor,AP-2,Clathrin,Cardiac hypertrophy,fibrosis, | en |
| dc.relation.page | 89 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2013-11-12 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
| 顯示於系所單位： | 生物化學暨分子生物學科研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 4.91 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。